Cancer patients with bone complications prefer infusion of zoledronic acid.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D015337:Multicenter Studies as Topic; D000077268:Pamidronate; D017060:Patient Satisfaction; D013997:Time Factors; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate